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Abstract
Background: Purine catabolism may be an unappreciated, but important component of the homeostatic response of
mitochondria to oxidant stress. Accumulating evidence suggests a pivotal role of oxidative stress in schizophrenia
pathology.
Methodology/Principal Findings: Using high-pressure liquid chromatography coupled with a coulometric multi-electrode
array system, we compared 6 purine metabolites simultaneously in plasma between first-episode neuroleptic-naı ¨ve patients
with schizophrenia (FENNS, n=25) and healthy controls (HC, n=30), as well as between FENNS at baseline (BL) and 4 weeks
(4w) after antipsychotic treatment. Significantly higher levels of xanthosine (Xant) and lower levels of guanine (G) were seen
in both patient groups compared to HC subjects. Moreover, the ratios of G/guanosine (Gr), uric acid (UA)/Gr, and UA/Xant
were significantly lower, whereas the ratio of Xant/G was significantly higher in FENNS-BL than in HC. Such changes
remained in FENNS-4w with exception that the ratio of UA/Gr was normalized. All 3 groups had significant correlations
between G and UA, and Xan and hypoxanthine (Hx). By contrast, correlations of UA with each of Xan and Hx, and the
correlation of Xan with Gr were all quite significant for the HC but not for the FENNS. Finally, correlations of Gr with each of
UA and G were significant for both HC and FENNS-BL but not for the FENNS-4w.
Conclusions/Significance: During purine catabolism, both conversions of Gr to G and of Xant to Xan are reversible.
Decreased ratios of product to precursor suggested a shift favorable to Xant production from Xan, resulting in decreased UA
levels in the FENNS. Specifically, the reduced UA/Gr ratio was nearly normalized after 4 weeks of antipsychotic treatment. In
addition, there are tightly correlated precursor and product relationships within purine pathways; although some of these
correlations persist across disease or medication status, others appear to be lost among FENNS. Taken together, these
results suggest that the potential for steady formation of antioxidant UA from purine catabolism is altered early in the
course of illness.
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Introduction
Schizophrenia (SZ) is a highly disabling disease characterized by
widespread structural and functional brain alterations, the
pathogenesis of which remains poorly understood. It has been
proposed that at least in part, the neuropathological changes in
this illness may result from oxidative stress mechanisms [1–10].
The precise components of such alterations remain unclear.
Biological systems have evolved complex protective strategies
against free radical toxicity. Under physiological conditions the
potential for free radical-mediated damage is kept in check by the
antioxidant defense system (AODS), comprising a series of
enzymatic and non-enzymatic components. These enzymes act
cooperatively at different sites in the free radical pathways.
Recently, we have observed that a dynamic state is kept in check
during the redox coupling under normal conditions [11]. By
contrast, lack of such correlations in brains of SZ patients point to a
disturbance of redox coupling mechanisms in the AODS, possibly
resulting from a decreased level of glutathione (GSH) as well as age-
related decreases of oxidized GSH and glutathione reductase
activities. Taken together, our previous data showing altered
membrane dynamics and AODS enzyme activities, and findings
from other investigators[8–10,12–13]areconsistentwith the notion
of free radical-mediated neurotoxicity in schizophrenia [2].
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9508There are multiple pathways to the production of excess free
radical generation and subsequent oxidative stress. One such
pathway is the formation of peroxynitrite by a reaction of nitric
oxide (NO) and superoxide radical. In human brain, NO is
metabolized primarily in the form of nitrate. A significantly
increased level of NO was found in brains with SZ than those of
normal and non-schizophrenic psychiatric controls [14]. Because
the reaction of NO with free thiols competes with the same
substrate (e.g., GSH), the excessive NO formation may further
lead to significant depletion of GSH in SZ.
Purine catabolism may be a previously unappreciated compo-
nent of the homeostatic response of mitochondria to oxidant stress
and may play a critical role in slowing progressive mitochondrial
dysfunction in certain disease states [15]. In response to oxidative
stress, decreased energy charge or nucleic acid damage, purine
metabolism shifts to favor breakdown to xanthine and uric acid.
Novel, powerful and rapid multidimensional separation and
characterization methods, e.g., high-pressure liquid chromatogra-
phy coupled with a 16-channel coulometric multi-electrode array
system (HPLC-CMEAS), can lead to revolutionary changes in our
understanding at the molecular level [16–19]. The resolving power
of these methods is superior to one-dimensional approaches,
enabling the comprehensive metabolic analyses particularly in the
targeted biochemical pathways. These techniques, applied to
investigate plasma, can provide valuable insights in the antioxidant
defense system involving purine catabolism.
In this study, we compared metabolic signatures consisting of 6
purine-degraded products simultaneously in the plasma between
first-episode neuroleptic-naive patients with schizophrenia
(FENNS, n=25) and healthy controls (HC, n=30) as well as
between FENNS at baseline (BL) and 4 weeks (4w) after
antipsychotic treatment. Studies of FENNS patients offer an
opportunity to investigate neurobiological alterations without the
potential confounds of antipsychotic medications and illness
chronicity. The data collected from HPLC-CMEAS allow
multiple rather than single metabolites to be used in markers for
a group, which will greatly improve the predictive value for
phenotypes that directly involved in the oxidative stress. More
significantly, these comprehensive analyses that generate meta-
bolic profiles represent not only biomarkers for disease but also
metabolic maps that can be used to identify specific genes
responsible for disease [20]. We hypothesized that the production
of antioxidant uric acid would be altered via the purine pathway in
the FENNS patients. Such a homeostatic imbalance of purine
catabolism may provide us with a biochemical index to predict
therapeutic outcome.
Results
Tests of Difference in the Group Locations
Descriptive statistics for all the analytes, by group, appear in
Table 1. Xanthosine (Xant) had 21 values measured at the same
Table 1. Descriptive statistics of metabolites in purine pathway.
Groups Mean Median Firstqrt Thirdqrt p (HC vs FENNS)* p (BL vs 4w)
{
1. HC
UA 50606
{ 41927 30460 66970
Xan 183 87 52 171
Xant 40 11 7.53 22
G 6.57 6.51 3.07 8.66
Gr 9.65 7.40 2.82 11
Hx 1079 354 139 734
2. FENNS-BL
UA 37007 25663 20074 46560 0.0193
Xan 177 70 63 136 0.8210
Xant 80 34 19 53 0.0023
1
G 3.79 1.98 1.12 6.02 0.0156
Gr 13 7.58 2.82 18 0.5771
Hx 1190 412 200 865 0.8867
3. FENNS-4w
UA 36322 25163 21556 47095 0.0124 0.7510
Xan 103 65 57 98 0.1977 0.1014
Xant 43 25 21 48 0.0081 0.5965
G 2.31 1.30 0.84 2.83 0.0002 0.0003
Gr 7.79 2.82 2.82 8.71 0.2502 0.0405
Hx 662 347 170 817 0.6935 0.4261
* Wilcoxon rank sum test.
{ Wilcoxon signed ranks test.
{Each value represents ng/mL. Xant and Gr have some left-censored values, so the listed mean estimates may be too large by up to 3.76 (HC), 0.60 (FENNS-BL), 1.20
(FENNS-4W) for Xant, and 0.94 (HC), 0.79 (FENNS-BL), 1.47 (FENNS-4W) for Gr.
1 Significance with p,0.0083 in boldface, trends with p,0.0167, after Bonferroni correction.
Abbreviations: HC, healthy control subjects; FENNS, first-episode neuroleptic-naı ¨ve patients with schizophrenia; BL, baseline; 4w, 4-week treatment with antipsychotic
drugs; UA, uric acid; Xan, xanthine; Xant, xanthosine; G, guanine; Gr, guanosine; Hx, hypoxanthine.
doi:10.1371/journal.pone.0009508.t001
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values, 2 FENNS-BL, and 4 FENNS-4W), and guanosine (Gr) had
30 values censored below at a lower threshold for all groups (10
HC values, 7 FENNS-BL, and 13 FENNS-4W). These unknown
true values thus range from 0 to the respective low threshold values
for Xant and Gr. In Tables 1 and 2, these data were used to
compute descriptive statistics using their low threshold (tied)
values. The medians and quartiles of Table 1 are thus unaffected,
while the means and standard deviations will contain systematic
errors, as described in the footnotes of each table. The
nonparametric Wilcoxon rank-sum and Kendall tau correlation
tests use ranks and accommodate tied values. The use of less
extreme values in place of the more extreme true values within a
small range, may be seen as increasing robustness, whether in
numerator or denominator, as for ratios. For the logistic regression
classifier, we found that neither Xant nor Gr contributed
significantly to the model, whether the threshold values were
included or these values were removed.
Nonparametric Location Testing
The Wilcoxon rank-sum tests showed higher Xant (median,
34.00 ng/mL) in FENNS-BL compared to HC (median,
10.47 ng/mL, p=0.0023, Table 1). After 4-week treatment with
antipsychotic treatment, Xant levels (median 24.78 ng/mL) were
reduced but remained statistically higher than those of the HC
group. Trend-level differences are also noted for uric acid (UA)
and guanine (G) between FENNS-BL patients and HC. The
values of both UA and G were lower in patient groups than in HC.
In addition, G was further reduced in FENNS patients after
treatment (p=0.0003).
The diagnostic groups also showed differences in post-hoc
comparisons involving a set of 13 ratios of analytes (Table 2),
selected to reflect the product and substrate relationships as
described in the purine pathway. The ratios of G/Gr, UA/Gr,
and UA/Xant were significantly lower, whereas the ratio of Xant/
G was significantly higher in FENNS-BL patients than in HC
subjects after the Bonferroni correction, acorr=0.05/13=0.0083.
Such differences remained for these patients after 4-week
antipsychotic drug treatment with the exception that the ratio of
UA/Gr was restored to the levels of the control group. Specifically,
the UA/Gr ratio was significantly (p=0.0025) elevated in
FENNS-4w patients as compared with the same individuals at
baseline. On the other hand, such a ratio was no longer
significantly different between FENNS-4w (704765556, mean 6
SD) and HC (737164325) groups (Table 2).
The effects of covariates gender, age, and Body Mass Index
were considered in the analysis. Although there were imbalances
of these in the patient and control groups, none of these covariates
showed a significant rank correlation with any analyte concentra-
tions for any of the pooled pairs of diagnostic groups. When
diagnosis effects upon the analytes were studied within covariate-
defined subgroupings (male/female, over/under median age,
below/above median BMI), significant results were found only
for those analytes already showing significance without subgroup-
ings, and these significant differences were in the same directions
as the results without the subdividing.
Logistic Regression Group Classifier
Furthermore, we built a classification model using logistic
regression to assess the performance of the purine pathway
analytes in separating the groups in space. In comparing HC to
FENNS-BL, lower G (deviance reduction 6.03 on 1 df,
Pr(x
2)=0.01) indicated membership in the FENNS-BL group
over the HC group. The G model correctly classified 17/25 (68%)
FENNS-BL patients and 20/30 (67%) HC subjects. Five-fold
cross-validation found that the estimated prediction errors (EPE,
Table 2. Comparisons of ratios of product to precursor in purine pathway between healthy control subjects and FENNS patients
and between FENNS patients before and after antipsychotic treatment.
Ratios HC FENNS-BL FENNS-4w p
HC vs BL* HC vs 4w* BL vs 4w
{
G/Gr
{ 0.8960.61
1 0.3760.30 0.4860.72 0.0004
" 0.0009 0.8949
Xan/Gr 25.51642.41 24.88637.02 24.95643.27 0.3598 0.5627 0.2872
Xan/G 46.33685.46 81.92698.86 66.68650.91 0.0211 0.0015 0.7112
UA/Gr 737164325 415262193 704765556 0.0015 0.4967 0.0025
UA/G 11998611525 16529614751 23771614948 0.0614 ,0.0001 0.0236
UA/Xan 5086266 3736246 4596208 0.0393 0.5074 0.0551
Xan/Xant 18.66631.78 8.54614.30 7.47617.33 0.0524 0.0107 0.3388
UA/Xant 507364845 12986972 218464310 0.0021 0.0067 0.5782
Xan/Hx 0.3160.18 0.4160.51 0.3160.31 0.6689 0.2491 0.2200
UA/Hx 1716124 1376144 1456147 0.1861 0.3255 1.0000
Xant/Gr 7.58615.35 9.03613.60 9.40615.02 0.0892 0.0099 0.2635
Xant/G 10.48615.58 42.02675.08 31.35627.93 0.0009 0.0001 0.2752
Xant/Hx 0.1860.36 0.8462.67 0.2060.24 0.1805 0.0614 0.7915
* Wilcoxon rank sum test.
{ Wilcoxon signed ranks test.
{ Abbreviations: Gr, guanosine; G, guanine; Xan, xanthine; UA, uric acid; Xant, xanthosine; Hx, hypoxanthine.
1 Mean and standard deviation. Means and standard deviations involving Xant and Gr are somewhat inaccurate due to the use of the low threshhold censoring value in
place of the unknown true concentration value.
" Significance with p,0.0038 in boldface after the Bonferroni correction.
doi:10.1371/journal.pone.0009508.t002
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models with more than one variable were not any better than that
of the single-variable G model (Figure 1).
In comparing HC to FENNS-4w, lower G levels (deviance
reduction 17.32 on 1 df, Pr(x
2)=0.00003) indicated membership
in the FENNS-4w group as opposed to the HC group. The model
correctly classified 19/25 (76%) FENNS-4w patients and 21/30
(70%) HC subjects, so neither model achieved highly accurate
classification. The cross-validation results found the G model
lowest in EPE. None of the analytes made a significant
contribution to a model attempting to classify the drug-naive state
versus drug-treated state of the patients, whether assessed by
deviance reduction or by cross-validation.
Testing for Nonzero Correlations
We also sought to determine which correlation coefficients
among selected pairs of analytes were significantly different from
zero (two-tailed). Since the data were not normally distributed,
Kendall’s Tau rank correlation coefficients were used to test the null
hypotheses of t=0. Bonferroni confidence intervals, or equivalent-
ly, modified p-values, were used for control of Type I error. For
display purposes, all p-values were multiplied by the correction
factor of 13, the number of the pairs of purine pathway variables
that were of interest to test (Figure 2), i.e., having product-precursor
relationships. Thus, p-values,0.05 were significant (Figures 3–5);
any modified p-values .1 were replaced with 1.
Within the Purines’ Pathway, all 3 groups had significant
correlations between G and UA, and Xan and Hx (Figure 3). By
contrast, correlations of UA with each of Xan and Hx, and
correlation of Xan with Gr were all quite significant for the HC
group but not for the FENNS group before or after treatment
(Figure 4). Finally, correlations of Gr with each of UA and G were
significant for both HC and FENNS-BL groups but not for the
FENNS group after antipsychotic drug treatment (Figure 5). Care
was taken to interpret any disparities in significance of a
correlation across the subject groups in concert with other
findings, as these disparities were not tested as explicit rejections
of hypotheses of zero difference in the correlation coefficients of
the respective groups.
Discussion
Homeostatic Imbalance of Purine Catabolism
In mammalian cells, purines are synthesized de novo from amino
acids, formate and carbon dioxide as nitrogen and carbon donors.
In addition to their major role in cellular energy metabolism,
purines (e.g., ATP) also function as neurotransmitters that are
Figure 1. Cross-validation (5-fold) for the logistic regression
classifier of HC vs FENNS-BL groups. A series of models was chosen
by forward selection using as criterion the minimizing of the estimated
prediction error (22 x log likelihood), displayed for each model 6 its
own standard error. Note that predictors are plasma purine concentra-
tions, only guanine (x=1) is significant contributor (since its prediction
error is within the standard error bar of the 4-variable model, which is
the lowest in prediction error). Abbreviations: HC, healthy controls;
FENNS-BL, first-episode neuroleptic-naı ¨ve schizophrenic patients at
baseline.
doi:10.1371/journal.pone.0009508.g001
Figure 2. Altered purine catabolism in first-episode neuroleptic-naı ¨ve patients with schizophrenia (FENNS). Metabolites identified by
purple color were measured in the present study. Red arrows indicate shifts toward an increase of xanthosine and a decrease of uric acid productions
in FENNS patients at baseline. Reactions shown with dotted lines represent the ‘‘salvage pathways’’, which purine bases can be reutilized resulting in
considerably energy saving for the cell. Abbreviations: NP, nucleoside phosphorylase; DA, deaminase; HL, hydrolase; XO, xanthine oxidase; HGPRT,
hypoxanthine-guanine phosphoribosyl transferase; PRPP, 5-phosphoribosyl pyrophosphate; AMP, adenosine monophosphate; ATP, adenosine
triphosphate; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; GMP, guanosine monophosphate; GTP, guanosine triphosphate; IMP,
inosine monophosphate; XMP, xanthosine monophosphate.
doi:10.1371/journal.pone.0009508.g002
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potentials [21]. Nucleotides (e.g., inosine monophosphate or
IMP) are phosphate esters of the purine nucleosides. The tri-
and diphosphates of the nucleosides are found in normally
functioning cells to a greater extent than the monophosphate
nucleosides. IMP is not present in the cells under normal
conditions and is converted to adenine, xanthine, and guanine
nucleotides by the pathways shown in Figure 2. Under resting
Figure 3. Significant correlations of uric acid to guanine, and xanthine to hypoxanthine in healthy control subjects (A), first-
episode neuroleptic-naı ¨ve schizophrenic (FENNS) patients at baseline (B), and FENNS patients after 4-week treatment with
antipsychotic drugs (C). The p values correspond to the computed values of Kendall’s tau rank correlations.
doi:10.1371/journal.pone.0009508.g003
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(SAH) by the enzyme SAH hydrolase. Extracellular adenosine is
rapidly removed in part by conversion to AMP by adenosine
kinase, and in part by degradation to inosine by adenosine
deaminase. Subsequently, inosine is converted to Hx by the
enzyme nucleoside phosphorylase (NP).
During the de novo synthesis of purine nucleotides, many
reactions require a great deal of energy utilizing the hydrolysis
of ATP. To provide ‘‘energy saving’’ for the cell, the purine bases
can be reutilized via ‘‘salvage pathways’’ [22] by converting
adenine, guanine or Hx to AMP, GMP or IMP, respectively
(shown dotted arrow in Figure 2). The unsalvaged Hx is then
converted to xanthine (Xan), which is further converted to uric
acid (UA) by xanthine oxidase. In man, UA is the final product of
purine catabolism [21], which has been implicated as a risk factor
and cause of numerous pathological conditions (see below).
In the present study, we evaluated the purine pathway by
quantitative determinations of six major purine metabolites
consisting of xanthosine (Xant), Xan, Hx, G, Gr, and UA. During
the purine degradations, both conversions from Gr to G and from
Xant to Xan are readily reversible (Figure 2). Altered ratios of
product to precursor, i.e., significantly decreased ratios of G/Gr,
UA/Gr and UA/Xant, and the increased ratio of Xant/G
(Table 2), suggested a shift favorable to the Xant formation
(approximately 2-fold increase) in the FENNS patients. Conse-
quently, the potential for steady formation of antioxidant uric acid
from purines was reduced at first testing of the patients, which is
shown in the red arrow of Figure 2. More importantly, such an
imbalance in purine catabolism is observed independent of
treatment since patients were neuroleptic-naı ¨ve at entry into the
study.
An early study by Kristal et al. [15] suggested that purine
catabolism may contribute to mitochondrial antioxidant defense
by producing the antioxidant UA. Failure to maintain elevated
xanthine and UA occurred contemporaneously with progressive
mitochondrial dysfunction. In accordance with our previous
findings of significant decreases of plasma UA levels in either
FENNS patients [23] or clinically stable patients with chronic SZ
[24], the present data provide further support of a defect in the
antioxidant defense system in SZ [1–10]. Recently, an altered
Figure 4. Significant correlations of uric acid to xanthine, uric acid to hypoxanthine, and xanthine to guanosine in healthy control
(A) subjects, but not in first-episode neuroleptic-naı ¨ve schizophrenic (FENNS) patients at baseline (B) and FENNS patients after 4-
week treatment with antipsychotic drugs (C). The p values correspond to the computed values of Kendall’s tau rank correlations.
doi:10.1371/journal.pone.0009508.g004
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cocaine addiction [25] or opioid dependence [26], although
plasma UA levels remained unchanged. It is not clear whether
such changes in purine metabolites without affecting plasma UA
levels would eventually lead to oxidative damage in substance
abusers.
Figure 5. Significant correlations of uric acid to guanosine, and guanine to guanosine in healthy control (A) subjects, and first-
episode neuroleptic-naı ¨ve schizophrenic (FENNS) patients at baseline (B), but not in FENNS patients after 4-week treatment with
antipsychotic drugs (C). The p values correspond to the computed values of Kendall’s tau rank correlations.
doi:10.1371/journal.pone.0009508.g005
Purine Catabolism in SZ
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(AODS)
Uric acid (UA) is mainly synthesized from adenine- and
guanine-based purines by the enzyme xanthine oxidase through
the purine catabolism (Figure 2), and seems to be endproduct of
purine catabolism in man. The blood levels of UA depend upon
the dietary intake of purines, biosynthesis of UA and the rate of
UA excretion [27]. Furthermore, the plasma levels of UA are
regulated by a renal transport system consisting of glomerular
filtration, reabsorption, secretion, and postsecretory reabsorption
components [28]. In the majority of mammals (but not in man),
UA is further converted to allantoin by urate oxidase (uricase).
Contrary to the traditional understanding as a metabolically inert
and waste compound without any physiological significance, UA is
a major, natural antioxidant contributing to approximately 60% of
the free radical scavenging activity in human blood [29].
Past studies have demonstrated that UA and inosine (precursor
of UA) may be beneficial in the treatment of oxidative stress
related neurodegenerative diseases [30–34]. Also, UA may assist in
the removal of superoxide by preventing the degradation of
superoxide dismutase, which subsequently inhibits its reaction with
nitric oxide (NO) to form peroxynitrite [35]. UA can also
neutralize peroxynitrite [36] and hydroxyl radicals [37] to inhibit
protein nitration [38] and lipid peroxidation [39], respectively.
Recent investigations further indicated that UA via astroglia may
protect dopaminergic neurons from glutamate toxicity [34,40].
Moreover, UA prevents the propagation of oxidative stress from
the extracellular to the intracellular milieu by preserving the
integrity of the plasma membrane at the lipid-aqueous interface
boundary [41]. High K
+-induced depolarization amplifies neuro-
protection provided by UA through a mechanism involving Ca
2+
elevation and extracellular signal-regulated kinasesK (ERK1/2)
activation (Figure 6). Thus, decreased plasma UA levels may
reflect decreased ability of the body to prevent superoxide and
peroxynitrite from damaging cellular components [27]. At
increased levels, however, UA may be considered as a marker of
oxidative stress [42,43] due to accumulation of reactive oxygen
species [44]. Therefore, UA can be served as both anti- and
prooxidant in the AODS (Figure 6).
Abnormally high levels of plasma (or serum) UA have been
related to cardiovascular disease, gout, hypertension, and renal
disease [45–49], whereas low levels of plasma (or serum) UA have
been linked to Alzheimer’s disease, multiple sclerosis, optic
neuritis, and Parkinson’s disease [40,50–54]. Although some
studies have indicated that plasma (or serum) UA may play a
role in the development or progression of such diseases
[45,47,49,55,56], it remains unclear whether an increased UA
contributes to the cause or is simply a consequence of these
pathologic conditions [27].
Lacking Control Mechanism in Purine Catabolism
There are three major purine bases and their corresponding
ribonucleosides formed in purine catabolism, consisting of adenine/
adenosine, guanine (G)/guanosine (Gr), and hypoxanthine (Hx)/
inosine (Figure 2). When comparing the ratios of product and
precursor within the purine pathway, Figures 3–4 have shown the
existence of tight product-precursor correlations in those conver-
sions ofGr to UA (via G and Xan),and ofHxto UA (via Xan) inthe
HC subjects. Interestingly, some of these correlations (i.e.,
conversion of Hx to Xan) persist across disease or medication
status, others (i.e., conversions of Gr to Xan, and Xan to UA) are
lost among FENNS patients. Although levels of UA are not
significantly correlated with Hx in the patient groups (Figure 4),
such a lack of correlation is likely due to the insignificant correlation
between UA and Xan, and not conversion of Hx to Xan.
Similar findings of lacking a control mechanism used by HC
subjects were also demonstrated in the tryptophan pathway from
these same FENNS [57], indicating some metabolite interactions
withinpurinecatabolism were alsoaltered in FENNS-BL (Figure 2).
Effect of Antipsychotic Treatment
Using Wilcoxon signed rank test, we found possibly lower levels
of plasma UA in FENNS-BL (p=0.0193) and FENNS-4w
(p=0.0124) patients than in HC subjects (Bonferroni corrected
acorr=0.10/6=0.0167, see Table 1). In the present study, there
were no significant differences in FENNS patients (n=25) before
vs after 4 weeks of antipsychotic treatment. Previously, applying
the controlled discontinuation of haloperidol in patients with
chronic SZ, we have conducted evaluation of antipsychotic drug
effects on plasma UA levels [24]. Plasma UA levels were also
found to be significantly lower in patients both on- and off-
treatment with haloperidol than in normal volunteers. Further-
more, plasma UA levels were marginally significantly higher in
patients treated with haloperidol than in the same individuals
(n=34) after haloperidol withdrawal.
On the other hand, there was a significant reduction of guanine
(G) in FENNS-4w patients as compared with either HC volunteers
or FENNS-BL patients (Table 1). In addition, using the Kendall
tau method, significant correlations between Gr and UA (or G)
shown in HC and FENNS-BL groups appeared to be lacking in
FENNS-4w patients (Figure 5). Our findings indicated that the
conversion of Gr to UA through G and Xan intermediates was
affected by the antipsychotic drugs, consistent with our data that
significant product-precursor correlations between UA and Gr,
and between G and Gr were disrupted after 4-w treatment of
antipsychotic treatment (Figure 5). Furthermore, the significantly
decreased ratio of UA to Gr in FENNS-BL patients could be
normalized in FENNS patients after 4w antipsychotic treatment
(Table 2); suggesting that UA/Gr ratio may be a biochemical
predictor for therapeutic outcome.
Taken together, reduced levels of plasma UA in patients with
schizophrenia were not likely the result of antipsychotic treatment.
In fact, antipsychotic treatment may increase the concentration of
UA through the purine catabolic pathway converting Gr to UA
(Figure 2).
Effect of Other Medications or Pathological Conditions
Reduced levels of UA are seen with a variety of medications
(allopurinol, aspirin, probenacid, coumadin, corticosteroids), liver
disease, alcohol use, Wilson’s disease, hemochromatosis, protein or
purine deficiency, xanthine oxidase deficiency, syndrome of
inappropriate ADH secretion (SIADH) or renal tubule disease
[58]. None of these drugs or pathological conditions are likely to
account for low plasma UA in our patients.
I nar e p o r to f3c h r o n i cs c h i z o p h r enic patients, hypouricemia was
found in association with long-term polydipsia-hyponatremia syn-
drome [59]. However, patients in the present study were healthy, with
no evidence for liver or kidney disease or significant calorie restriction.
The reductions in patients of plasma UA were within normal limits,
suggesting that the lowered levels are not indicative of ongoing disease
processes (other than SZ) that can affect the antioxidant UA. Rather,
the lowered levels may reflect subtle changes indicating either the
acute phase response [60,61] or oxidative stress [2].
Effect of Cigarette Smoking on Antioxidant Capacity
Patients with schizophrenia smoke at very high rates [62].
Smoking, in turn, is associated with oxidative stress and decreases
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major compounds in the gas phase of tobacco smoke is nitric
oxide. It has been suggested that nitric oxide reacts with smoke
olefins to form carbon-centered radicals [63]. On the other hand,
the tar phase consists of a semiquinone radical that promotes
hydrogen peroxide formation. Moreover, tobacco smoke may
increase free radical formation by activating neutrophils.
We have previously demonstrated that plasma antioxidants
including uric acid are not affected by smoking status in patients
with chronic schizophrenia [24]. Furthermore, there were no
significant differences on plasma antioxidant measures between
nonsmokers (n=18) and smokers (n=13) in the FENNS patients
[23]. Among nonsmoking groups, plasma UA levels remained
significantly lower in the FENNS patients than in HC subjects
[23]. Thus, the altered purine catabolism in schizophrenia cannot
be accounted for by smoking alone.
Effect of Dietary Intake
It is possible that differences between FENNS patients and HC
subjects in this study can be accounted for by environmental
factors, such as diet, which is known to affect both the antioxidant
system and the production of free radicals [66]. All subjects in the
present study were recruited from the general population, without
a controlled diet. Although specific dietary history was not
documented for each subject, the body mass indices (BMI) were
higher in normal control subjects than in FENNS (Table 3),
suggesting that dietary factors could account for the findings. In a
previous study examining plasma UA in patients with chronic SZ
who were hospitalized and maintained on a controlled and
balanced diet without alcohol consumption [24], a correlation
between BMI and plasma UA was found in patients but not
normal controls. Moreover, the BMI was higher in patients with
chronic SZ than normal controls. By contrast, in the present study
Figure 6. Possible mechanisms involving promotion and removal of free radicals by uric acid. Abbreviations: Xan, xanthine; XO, xanthine
oxidase; SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; O2 ¯N, superoxide anion radical; H2O2, hydrogen peroxide; NO
N, nitric oxide; ONOO
¯,
peroxynitrite; NO2
N, nitrogen dioxide radical; OH
N, hydroxyl radical; LOO
N, lipid peroxyl radical; LVCa, L-type voltage-gated calcium channel; ERK1/2;
extracellular signal-regulated kinases1/2.
doi:10.1371/journal.pone.0009508.g006
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significantly lower plasma UA levels present in both neuroleptic-
free chronic [24] and treatment-naı ¨ve [23] patients with SZ. Thus,
it is unlikely that decreased plasma uric acid level in SZ patients
resulted from alterations in BMI.
Oxidative Stress and Schizophrenia
Schizophrenia is a major mental disorder without a clearly identified
pathophysiology. This is also true for bipolar disorder and major
depression. While these conditions have distinctive clinical phenotypes,
there appear to be pathophysiological similarities that suggest
pathogenetic pathways that may be common to these disorders. There
is increasing evidence of antioxidant defense system (AODS) deficits in
schizophrenia [1–10]. A significant contribution to the body’s total
antioxidant capacity comes from antioxidant molecules in plasma, such
as albumin, uric acid and bilirubin. Significant reductions of plasma
antioxidants (e.g., albumin, bilirubin and uric acid) are seen early in the
course of schizophrenia [23] and the present study, consistent with
previous findings in patients with chronic schizophrenia [2,7]. More
importantly, these reductions are observed independent of treatment
since patients were antipsychotic drug-naı ¨ve at entry into the study.
The critical antioxidant enzymes including superoxide dismu-
tase, catalase and glutathione peroxidase (Figure 6) act coopera-
tively at different sites in the free radical pathways. Non-enzymatic
antioxidant components, may be equally important in the overall
AODS, include uric acid, albumin, bilirubin, glutathione, a-
tocopherol (vitamin E), ascorbic acid (vitamin C), and b-carotene.
Oxidative stress in brain occurs when the generation of reactive
oxygen species overrides the ability of endogenous antioxidant
systems to remove excess reactive oxygen species subsequently
leading to cellular damage [67]. Increasing evidence suggests that
mitochondrial pathology and oxidative stress may be the most
critical component in the pathophysiology and outcome of
schizophrenia [1–10,68,69].
As discussed earlier, we [11] have observed that a dynamic state
is kept in check during the redox coupling under normal
conditions. By contrast, our observation of lack of such
correlations in brains with schizophrenia point to a disturbance
of redox coupling mechanisms in the antioxidant defense system,
possibly resulting from a decreased level of glutathione (GSH) and
age-related decreases of oxidized GSH and glutathione reductase
activities. In addition, we have also shown a significantly higher
level of nitric oxide (NO) in schizophrenia brains than in those of
normal and non-schizophrenia psychiatric controls [14]. Taken
together, our present data showing homeostatic imbalance of
purine catabolism and earlier data showing altered membrane
dynamics and antioxidant defense system enzyme activities, and
other findings of abnormal GSH gene [6,9,70] and SOD gene
[71,72] are consistent with the notion of free radical-mediated
neurotoxicity in schizophrenia.
Limitations
In the presentinvestigation, wehave not carried out data analyses
of biochemical correlations to clinical measures regarding symptom
expression and illness severity because other related pathways and
cross-pathway relationships are currently under investigation. To
provide a better context, we will seek clustering of, and biological
meaning in, finding of group differences. This approach will seek
clinical-biochemical associations by targeting key biochemical
variables instead of pursuing large-scale multiple testing.
Materials and Methods
Subjects
First-episode neuroleptic-naı ¨ve (FENN) patients. Twenty
five patients were recruited (Table 3) in their first episode of
psychosis after they provisionally met DSM-IV criteria for
schizophrenia, schizophreniform or schizoaffective disorder
based on Structured Clinical Interview for DSM Disorders
(SCID). The initial diagnostic assessments were performed at
consensus diagnostic conferences including SCID and all clinical
data, and attended by research faculty and staff, chaired by one of
authors (MSK or DM). All subjects signed informed consent after
a full explanation of the study. The study was approved by both
VA Pittsburgh Healthcare System and the University of Pittsburgh
Institutional Review Board. Blood samples were obtained in
patients at baseline (FENNS-BL) prior to the initiation of
antipsychotic agents. A second set of blood samples were
obtained in the same patient individuals about 4 weeks after
treatment (FENNS-4w) with one or more of the following
antipsychotic drugs: risperidone (n=17), olanzapine (n=4),
quetiapine (n=2), aripiprazole (n=1) and haloperidol (n=2).
The number adds up to more than 25 because of polypharmacy.
Clinical symptoms were rated by experienced research clinicians
at both time points using standard rating scales: Brief Psychiatric
Rating Scale (BPRS) [73], Scale for Assessment of Positive
Symptoms (SAPS) [74], Scale for Assessment of Negative
Symptoms (SANS) [75], and Global Assessment Scale (GAS)
[76]. The clinical symptom scores including BPRS, SAPS and
Table 3. Subject characteristics.
Demographical
features Healthy controls (HC) FENNS*
Male Female Male Female
Number 18 12 19 6
Age (yrs) 22.564.5 23.264.6 21.465.5 26.3610.6
Age of onset (yrs) --- --- 18.866.8 23.969.54
Illness duration (yrs) --- --- 1.2361.29 2.4362.22
Educations (yrs) 14.363.1 13.962.3 11.862.9 12.364.6
Weight (kg) 84.3618.1 63.768.8 70.8619.7
{ 54.468.7
{
Height (cm) 179.368.1 164.866.6 173.2610.4 163.364.3
Body mass index 26.665.4 23.863.0 23.964.8 20.763.0
*FENNS, First-episode neuroleptic-naı ¨ve patients with schizophrenia including
10 undifferentiated type, 2 paranoid type, 3 disorganized type, and 2 residual
type; 7 schizoaffective disorder; and 1 schizophreniform disorder.
{p=0.0357 (HC-male vs FENNS-male, unpaired, 2-tailed t-test).
{p=0.0597 (HC-female vs FENNS-female, unpaired, 2-tailed t-test).
doi:10.1371/journal.pone.0009508.t003
Table 4. Clinical assessments.
Rating scales Baseline 4-week follow-up P*
Brief Psychiatric Rating Scale (total) 52.5868.9 42.9167.5 0.001
Scale for Assessment of Positive
Symptoms
24.29611.03 14.21612.14 0.001
Scale for Assessment of Negative
Symptoms
45.46610.35 42.1768.25 0.072
Global Assessment Scale 30.4269.3 38.46611.51 0.001
* Wilcoxon signed ranks test; two-sided.
doi:10.1371/journal.pone.0009508.t004
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antipsychotic drugs (Table 4).
Healthy controls. Subjects (n=30) recruited from the same
neighborhoods were matched to the patients by their age, gender
and educational level through local advertisement. Subjects with
previous exposure to antipsychotic agents, substance abuse or
dependence within the preceding 6 months, systemic medical
illness requiring treatment, and neurological disorders were
excluded. None of the controls had any personal or family
history of psychosis.
Sample Preparation
All blood samples were collected in the morning after overnight
fasting. Samples were prepared for analysis by extraction in
acidified acetonitrile and analyzed by liquid chromatography with
electrode Coul Array (LCECA) system as previously described
[54,57]. Briefly, freshly drawn blood with anticoagulant citrate
dextrose (ACD) was centrifuged at 7506g for 7 minutes to remove
RBC and stored at 280uC freezer. 250 ml aliquot of stored sample
was mixed with 1 ml of acetonitrile/0.4% acetic acid at 225uC
and vortexed for 45–60 sec, then temperature was brought to
215uC in a cold block, and vortexed again for 30–45 sec. Samples
were centrifuged for 15 min at 12,0006ga t4 uC. In total, 1 ml of
the resulting supernate was transferred to a 2 ml screw top vial and
evaporated under vacuum. It is critical that the vacuum is
sufficient to freeze the sample during this step. The sample was
reconstituted in 200 ml of mobile phase A and 100 ml were loaded
onto two autosampler vials, one of which was archived at 280uC.
Profiles are stable in acetonitrile extract, dried extract and mobile
phase diluted extract.
During the sample preparation, pools were created from equal
volumes of aliquots of all samples. All assays were run in sequences
that include 10 samples, authentic reference standard mixtures of
80 known compounds, pools of all samples and duplicate
preparations of the same sample. Duplicates are spaced at short
and long intervals through the run to reflect the performance of
the total data base. Run orders of all samples in this study were
randomized. The sequences minimized possible analytical artifacts
during further data processing. Pools and duplicates were used to
access the precision of the entire data set. In addition, the pools
were used as references for time normalization (stretching). A
practical advantage of LCECA for this study is the relative
freedom from maintenance events. This is important for the
generation of consistent databases from large numbers of samples
over extended time periods. In our earlier work we have run
LCECA continuously for 24 h per day over 6 months.
High-Pressure Liquid Chromatography Coupled with
Electrochemical Coulometric Array (LCECA) Detection
The LCECA method used in this work has been described
earlier [19,57,77]. Briefly the liquid chromatographic method
employs an A mobile phase (10.3 g l
21 sodium pentane sulfonate,
5m ll
21 glacial acetic acid) and a B mobile phase (methanol/
acetonitrile/isopropanol 8/1/1, 8 g l
21 lithium acetate, 20 ml l
21
glacial acetic acid). A gradient is run from 100% A to 100% B over
120 min. The electrochemical array of 16 series coulometric
detectors is set from 0 to 900 mv in equal 60 mv increments from
detector 1–16. In this mode a compound passing through a
coulometric electrode is oxidized by 100% of the thermodynam-
ically possible amount. This results in a characteristic signature for
a compound expressed as a ratio on sequential electrodes. This
ratio provides a high degree of qualitative certainty, which can be
set for any particular study [77]. The gradient and detector
conditions typically provide responses at the 500 pg ml
21 level
(5 pg on column) for ca 1500–2000 compounds in biological
samples. In comparison with Mass Spectrometry (MS) a specific
thermodynamically determined response ratio and retention time
in an LCECA method does not carry as much qualitative certainty
as an accurate mass peak or fragmentation pattern in MS/MS.
However, in comparison with MS for the classes of compounds
measurable on LCECA the sensitivity of ca 500 pg ml
21 is
typically one to two orders of magnitude lower than can be
achieved with MS. As an example we conducted a study directed
at identifying metabolites implied by the presence of multiple
responses in an LCECA method following Huntington’s disease
patients treated with phenyl butyrate [78]. The LCECA method
employed 40 ml of plasma. It was necessary to concentrate and
fractionate 4 ml of plasma to obtain sufficient material for
qualitative identification in a parallel LCECA/LCMS system.
The LCECA method with 100% efficient electron transfer also has
an inherent quantitative control based on integration of the total
coulombs of the peaks [78] and calculation of quantity by
Faraday’s law. Thus, it is independent of such factors as variations
in ionization efficiency as a result, for instance, of column bleed.
Inter-laboratory/inter-method comparisons are a field in and of
themselves. Well designed studies are highly expensive and have to
take into account standards, preparative methods, sample splitting
techniques and so on, as well as the instrumentation and
parameters of instrument usage. Initial efforts are frequently
discouraging. As an example the initial round of the multi center/
method ESCOT study for 8 hydroxy 29deoxyguanosine measure-
ments initially returned values differing by a factor of 1000 with
the higher values resulting from source artifacts in a gas
chromatography-mass spectrometry (GCMS) method.
Enzyme-linked immunosorbent assay techniques for this same
analyte in urine are typically comparable to electrochemical
methods for controls and standards but a factor of 2–5 higher in
various disorders, whereas GCMS techniques for this analyte in
CSF have been reported as 10,000 times higher compared with
electrochemical techniques.
Data Reduction and Analyses
All chromatograms in the study were background corrected
(BC) to eliminate the base line drift inherent in gradient profiles.
By controlling analytical conditions, the location of any particular
peak in a 16-channel 110 min chromatogram was held within
6(5–30) sec through the study. BC files were then sequentially
time normalized against a single pool in the middle of the study
sequence. A two-step stretching protocol with a multitude of peaks
was used. First, proprietary software (ESA, CEAS 512) was used to
align 15–20 major peaks in the chromatogram and interpolate the
positions between them. Then an additional 20–25 smaller peaks
present in most samples were selected from the derivative file and
those were realigned, keeping the major peaks in the same
position. Selected peaks were aligned within 60.5 sec and non-
selected peaks within 6(1–1.5) sec over the entire 110 min assay.
Data was exported in three formats. First all responses matching
the retention and EC signature of compounds in the reference
standard were exported in concentration units of ng ml
21. Second
all responses matching resolved peaks in the pool of all samples
were exported in terms of their relative response to the pool value.
The concentrations of these were subsequently estimated by the
total coulombs in the peak assuming a molecular weight of 200
and a two-electron charge transfer.
Third, in addition to determining the concentration levels of
peaks against standards and pools, we exported the analytical
information for all samples in digital format (digital maps) [78].
Using complete digital output served two purposes: (i) capture of
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avoiding possible artifacts introduced by peak-finding algorithms.
The number of variables in the digital maps depends on the
resolution set during the data export. In this work, the resolution
was set at 1.5 s and the number of data points (variables, defined
as the signal at a given time on a given channel) obtained from one
sample, using our current LCECA approach, was 66 000. It is
important to note that the number of variables in digital maps is
not equivalent to the number of analytes because an individual
analyte is represented by more than one variable. Depending on
the concentration of an analyte and on its separation across the
electrochemical array, the number of variables characterizing an
analyte could be between 10 and 100. In the consolidated files of a
study all variables were aligned in a spreadsheet for data analysis
with each column representing a single subject (sample) organized
by time from channel 1 to 16. Each row in a spreadsheet
represents the response of a compound (variable) at a specific time
and channel for all samples. This approach avoids artifacts in data
reduction and protects against overfitting in the data analysis.
Before data analysis, rows in the digital maps for which all values
were negative or ,30 pA (noise level of the analytical method), for
all samples were eliminated. The data were analysed by
conventional statistical methods and by partial least squares
discriminant analysis [79]. After finding the variables differenti-
ating the groups (for example, schizophrenic vs healthy controls),
we sorted the variables by retention time and channel. This step
allowed isolation of ‘peak clusters’ (that is, all digital map variables
characterizing one specific analyte), which, in turn, provides an
identification of specific markers. Then the most significant
variables in the digital maps were used to identify the location of
the actual marker peaks within the chromatograms.
Analysis of Purine Pathway
Generally, a metabolic pathway consists of sequential biochem-
ical reactions that generate various products from a set of
precursors. Thus, connections between biochemical reactions
through the substrate and the product metabolites form complex
metabolic networks that may be analyzed using network theory,
stoichiometric analysis, and information on protein structure/
function and metabolite properties [80]. In this study, estimates of
various enzyme activities in purine pathways were calculated using
the product to precursor ratios for each enzyme. The following
ratios were used: G/Gr, Xan/Xant, Xan/Gr, UA/Gr, UA/Xant,
and Xant/G, for purine nucleoside phosphorylase; Xan/G and
Xant/Gr, UA/G for deaminase; UA/Xan, Xan/Hx, UA/Hx,
and Xant/Hx for xanthine oxidase. The absolute value for each
purine metabolite was used for calculating the ratios. Significant
differences in such ratios were sought between patients, off or on
treatment with antipsychotic drugs, and healthy controls.
Statistical Analyses
All analyte variables were expressed as ng/ml of plasma. Three
groups of samples were analyzed: controls (HC, n=30), first-
episode neuroleptic-naı ¨ve schizophrenia patients at baseline
(FENNS-BL, n=25), and the same patients after 4 weeks of
antipsychotic treatment (FENNS-4w, n=25). Six analytes within
the purine pathway were measured, and descriptive statistics were
computed for each of the 3 groups according to the flow chart for
data analyses (Figure 7). The raw data were viewed by quantile-
quantile normal and chi-square plots, and by variable-pair
scatterplots, to assess normality and nonlinear relationships. Some
analytes had a number of identical minimum entries that had been
censored below. Not all analytes were normally distributed, so
hypotheses of no difference between the relative concentrations of
each analyte for pairs of the subject groups (HC, FENNS-BL,
FENNS-4W), were tested by nonparametric Wilcoxon rank sum
tests or Wilcoxon signed ranks tests, as appropriate. When ties
were present, the normal approximations for the above Wilcoxon
test statistics [81] were used in the tests. Control of Type I error for
this multiple testing process was effected by applying the
Bonferroni correction.
We used the rank correlation method of Kendall to examine
associations among all 6 analyte variables, within each subject
group. This method tests the null hypothesis of no rank correlation
among 2 variables whose distribution is not known, and can
accommodate tied or censored values up to the extreme case of
variables with dichotomous values [82]. Because two correlations,
those between Hx and G and between Hx and Gr, did not have
product-precursor relationships (Figure 2), we tested the remaining
[66(621)/2]22=13 Kendall tau-a correlations against the two-
sided alternative, using Bonferroni-corrected a=0.05/13=0.0038
(or a=0.10/13=0.0077), to determine which correlations were
clearly (or possibly) different from zero, for each group separately.
Gender, age, and body mass index (BMI) were available for all
but two control subjects, but some imbalances were present across
diagnostic groups (Table 3). The effects of gender groupings on
metabolite variables were examined by Wilcoxon rank sum tests,
and the associations of continuous covariates with the metabolites
were examined by Kendall’s tau correlations, to rule out covariate
effects masquerading as diagnostic group differences. We also
sought to discover any significant reversals of effects of diagnostic
Figure 7. Flow chart of data analyses.
doi:10.1371/journal.pone.0009508.g007
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metabolites within each one of pairs of subgroups defined by 2
levels of the covariates (male/female, below/above median age,
below/above median BMI). We sought rejections of the
hypotheses of no difference, with a set at the same level
(Bonferroni correction only for number of analytes) as for the
unsubdivided diagnostic group Wilcoxon testing, acorr of 0.5/
6=0.0083 (two-tailed), i.e., liberally admitting additional tests per
analyte without further correction.
Finally, the ability of the analytes to classify subjects by group
membership was examined by logistic regression [83]. A sequence
of models was generated by forward selection. Models were
assessed by deviance reduction, as well as by 5-fold cross-
validation, with estimated prediction error (EPE) approximated
by the negative log likelihood loss function [84]. K-fold cross-
validation is used to avoid ‘‘model error,’’ i.e., choosing models
suggested by random aspects of the data. One divides the N data
samples randomly into K nearly-equal portions, and leaves each
portion out, successively, while making K estimations of the model
parameters, giving K models. Then each of the K models is used
to compute the EPE for the corresponding left-out portion of the
data. The means and standard errors of the K EPE values are then
plotted as the process is repeated for the original large sequence of
models (with different numbers of analyte variables). A common
procedure for identifying a ‘‘best’’ model is to first find the model
with the lowest EPE value (see Figure 1), and then to select the
smallest model with EPE within one standard error of the lowest
EPE value [84].
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